univers coverag
calendar event
medic meet american associ clinic chemistri american associ
physicist medicin
half full half empti alzheim diseas puls call takeaway
averag dcf price-to-earnings p/sale
bottom line afternoon host medacorp puls call well-known amyloid
alzheim key opinion leader discuss sever controversi
elenbecestat present alzheim associ intern confer aaic
meet earlier week specialist self-describ believ amyloid hypothesi
therapeut potenti view reflect underli perspect key controversi
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
highlight call list discuss detail within bodi
signific imbal studi arm
view adcom alzheim diseas composit score endpoint trial
aria amyloid imag relat abnorm unavoid consequ drug effect
class aria better wors
elenbecestat data support amyloid hypothesi
could approv exist dataset eisai
 methodolog averag dcf price-to-earnings p/sale
bottom line morn report in-lin revenu small ep beat versu
consensu increas ep guidanc reflect strong howev
manag commentari guidanc somewhat cautiou left revenu
guidanc unchang guidanc includ expect hcv revenu declin
sequenti forecast global humira growth first single-digit growth
rate sinc humira perform undermin lack posit price us
share price loss biosimilar europ begin base quarterli
result manag comment guidanc lower revenu forecast
ep forecast price target reduc reiter market
perform rate abbvi stock could becom attract recent launch gather
momentum new launch get underway time comfort remain
sidelin even upsid adjust target price
guidanc increas margin perform share repurchas
previous cover highlight confer call recap note link
revenu mm dilut ep includ option expens present
pro-forma ebitda leverag
bottom line report revenu ebitda ep beat driven price better
expect volum reduc pt reflect cash flow headwind
increas interest expens rais revenu ebitda guidanc due time
close divestitur ep cffo guidanc lower due increas interest expens
recent debt refinanc remov near-term default risk account receiv ar collect also
cffo headwind due time divestitur ss revenu growth activ revenu cycl
manag initi improv cash flow focu higher acuiti servic line help
price well lower acuiti shift outpati close lower acuiti servic line volum
remain street expect make invest ambulatori improv adj
admiss expect leverag remain though focus reduc
term loan reach first lien flexibl debt repay
increas ebitda estim mm mm due time
divestitur lower pt
revenu ebitda ep beat driven price better-than expect volum improv
revenu ebitda guidanc rais delay time close divestitur
cffo guidanc lower mm due interest rate headwind sever payment
collect ar despit lower capital-expenditure divestitur
price remain solid servic line invest shift lower acuiti procedur ob lower
cost site servic also reflect hospit surgeri volum trend
volum remain street expect make invest ambulatori improv
oper expens manag also improv salari wage benefit swb opex
rais ebitda estim due time divestitur
expect leverag remain though focus reduc term loan
reach first lien flexibl debt repay
revenu million bad debt expens ep present ex one-tim item
slowli sure sight acceler improv pt
 methodolog cash ep
bottom line op rate predic view long-term orient investor
believ turnaround stori make new leadership compani
improv execut eventu drive faster ep growth compani come
side manufactur suppli recoveri post re-acceler top-lin given
potenti may even begin engag portfolio re-shap beyond
 shift exposur toward faster-grow end-mkts/subseg result leav
us increas confid turnaround trajectori remain intact organ revenue growth
acceler forecast achiev gener solid outlook increas hold market
lead posit across key ortho mkt trade signific p/ discount large-
cap med-tech think valuat gap narrow top-lin growth acceler unfold despit
slightli lower ep reduct fx-driven pt goe vs reflect higher
multipl vs sinc last valuat updat -- -due expand group multipl
increas confid management achiev steadi growth re-acceler trajectori ntm period
cc outlook tick slightli fx reduc report adj ep
respect chang model ep unchang remain in-lin
guidanc though ep lower reflect increment fx impact
suppli recoveri timelin reiter management tone call sound us increment
posit
management still project growth acceler trajectori toward market rate unchang within
million ep ex-amort
dcf analysi revenu multipl dr tgr
bottom line report financi result provid pipelin updat consist
prior guidanc recal compani lead proprietari product candid mirvetuximab soravtansin
antibody-drug conjug target folat receptor- current phase develop
forward-i single-ag platinum-resist ovarian cancer addit on-going
forward-ii phase i/ii studi evalu drug combin avastin keytruda carboplatin/
avastin advanced/metastat ovarian cancer next key catalyst stock forward-
ii keytruda combin data expect european societi medic oncolog esmo
 forward-i top-lin data expect medacorp kol spoken
express optim ahead forward-i phase readout link link addit
next-gen product candid partner op repres
sourc upsid view next clinic updat expect late year american societi
hematolog annual meet reiter op price target
revenu million ep fiscal year chang june dec
bottom line lpnt report ebitda beat due suppli swb salari
wage benefit expens report small revenu miss driven better expect
volum surprisingli weak price may impact health
hospic revenu guidanc lower ebitda guidanc rang tighten ebitda
mm line estim versu consensu mm volum beat expect
ss surgeri trend improv qoq yoy price surprisingli weak may
impact health hospic transfer swb suppli expens beat opex
miss call due pend apo nr privat equiti transact
retir
bottom line highlight rtrx earn call includ management report solid cash/c
market secur posit increment growth base busi three activ
registr trial retir ceo stephen aselag season
gross-to-net discount tailwind management report revenu came slightli
lower our/street estim repres yoy increas expect lion
share revenu gener thiola sale revenu note due
possibl generic asset management maintain plan file nda/new intellectu properti
improv thiola formul potenti enter market think may result
higher revenu multipl stock switch gear rtrx blockbust oppti rare kidney
diseas management comment enrol pivot duplex studi evalu lead
asset sparsentan focal segment glomerular sclerosi fsgs/probabl success po
remain track top-line readout interim analys pt set initi
pivot trial evalu sparsentan iga nephropathi igan second rare renal diseas
set remain enthusiast program encourag management proven
track record execut clinic move third pivot trial -- rtrx pantothen
kinase-associ neurodegener pkan program much anticip pediatr enrol
commenc steadi pace management guid enrol complet lastli
compani may expand clinic pipelin phenylketonuria pku choos acquir
base posit proof-of-concept poc data potenti set four pivot
studi taken togeth see divers base busi clinic pipelin
key driver gener meaning near- long-term valu rtrx stock
updat model reflect financi result reiter op pt
revenu million
bottom line report provid updat week end juli key product
watch
weekli iqvia im trend week end juli
bottom line note analyz iqvia formerli im script trend week end juli
harvoni epclusa vosevi mp mavyret mp zepati nr
hcv genvoya descovi odefsey biktarvi juluca gsk nr hiv tagrisso azn
nr lung cancer imbruvica abbv/jnj op zydelig venclexta abbv/rhhbi nr
hematolog malign ibranc nr kisqali nv nr verzenio nr breast
cancer xtandi zytiga prostat cancer cabometyx nr renal cell carcinoma
otezla celg op plaqu psoriasi psoriat arthriti cosentyx nv plaqu psoriasi
psoriat arthriti ankylos spondyl taltz plaqu psoriasi tremfya plaqu
psoriasi dupix sni nr/regn op eucrisa atop dermat kevzara sny/regn
rheumatoid arthriti tecfidera mp multipl sclerosi breo anoro incrus trelegi
gsk/inva nr chronic obstruct pulmonari diseas nucala gsk fasenra azn
asthma praluent sny/regn repatha mp entresto nv cardiovascular diseas
trulic jardianc basaglar toujeo soliqua sni tresiba xultophi ozemp
nvo nr diabet austedo teva huntington contrav orex nr obes ocaliva
mp primari biliari cholang intrarosa mp dyspareunia actemra rhhbi
immuno-oncolog aimovig migrain
digit front mco vs
set keep florida medicaid win
meaning could gener restasi teva
overdon bullish stemi commentari hint growth
ev/sal multipl estim
solid result net one-tim mg gather momentum pt
 methodolog averag dcf price-to-earnings
stabl enough portfolio challeng mount mp pt
 methodolog averag dcf price-to-earnings p/sale
ep
new product cycl drive continu growth acceler
pt deriv rang dcf valuat deriv base case upsid scenario
supplement ev/fcf ev/ebitda analys
solid result give relief pipelin need deliv
 methodolog averag method dcf price earn price sale
thv sale fall slightli expect acceler
ep
headwind persist global price pressur continu pt
 methodolog ep
 methodolog ev/ebitda ebitda
earn deal backlog still flat sequenti
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
note ph criteria differ nccn guidelin meant trial
result directli compar prior studi
discuss fda on-going primari endpoint determin
told endpoint may similar select ph design
link note
recent pamrevlumab result suggest convent ct scan may accur predict
resect lapc patient
success pamrevlumab neoadjuv set may depend chang resctabl
standard adopt clinic regulatori commerci endpoint
aug omadacyclin antibiot skin pneumonia adcom link
key catalyst remain time-frame conven adcom aug
potenti approv oct time-frame could move stock meaning
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
mid-august hire extern sale rep cologuard screen
cologuard highli under-penetr strong popul need
colorect cancer screen believ could deliv penetr
revenu longer term penetr ttm sale
recent analysi util leerink healthcar advanc analyt suggest
hire extern rep remain track complet mid-august earlier
timelin highlight
view revenu growth depend fast compani hire sale rep
particularli extern rep harder find hire intern one
turn drive new physician reorder catalyz growth exist physician order
rep hire faster abl reach new pcp aggress
abl serv exist account sooner and/or frequent -- ultim drive upsid
estim take month rep becom fulli product
result updat like late juli
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
gener restasi bridg goal date chronic dri eye see note
fda adcom joint meet drug safeti risk manag anesthet
fda adcom antimicrobi drug omadacyclin acut bacteri skin skin
structur infect absssi community-acquir bacteri pneumonia cabp
medcac panel t-cell therapi
fda public hear biosimilar silver spring md
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
american associ physicist medicin
american associ clinic chemistri
world congress cancer skin
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
deadlin lpnt solicit altern acquisit propos
go live az
model celg recent updat
pleas contact leerink repres wish review
biopharma preview gener pain women anti-infect
hcit distribut preview pocket opportun
medic suppli devic individu co preview cardio large-cap
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
note wild ride ahead aaic data could drive
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
hcit distribut -- flash minut stori appear one-sid
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
deal capac
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
 open ablat atriclip drive near term growth mi longer term
 differenti poc signific runway impli upsid pt
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
